The AKT inhibitor capivasertib in combination with fulvestrant resulted in significantly longer progression-free survival than fulvestrant alone in patients with hormone receptor-positive advanced breast cancer exhibiting disease progression during or after previous aromatase inhibitor therapy, with or without a CDK4/6 inhibitor [11]. Here, AKT1 is linked to breast cancer.